Wells Fargo has downgraded Exact Sciences Corp (EXAS) to Equal-Weight from Overweight, a move that suggests increased caution regarding the company's outlook. This action, taken on November 20, 2025, reflects potential concerns about competitive pressures and market conditions that could impact the firm's performance.
Exact Sciences, headquartered in Madison, Wisconsin, operates in the biotechnology sector and focuses on cancer screening and diagnostics. The company, which employs 6,900 full-time staff, offers a portfolio of products aimed at early cancer detection and treatment guidance, including its flagship Cologuard test. As of now, the stock is priced at $101.01, with a market capitalization of $12.7 billion and a trailing twelve-month EPS of -5.42.
Analyst ratings can provide valuable insights, but they are based on assumptions and estimates that may not always materialize as anticipated. As of November 1, 2025, the consensus among analysts is a Buy, with 12 Strong Buy, 14 Buy, and 4 Hold ratings. However, recent downgrades from multiple firms, including Wells Fargo and Barclays, indicate a shift in sentiment.
Investors should consider various factors, including company fundamentals and industry trends, when making decisions. Upcoming earnings reports are also on the horizon, with estimates suggesting an EPS of $0.12 and revenue of $935.7 million for August 4, 2026, following a projection of -$0.20 EPS and $847.4 million revenue for April 29, 2026.